Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Insulin lispro A · 1 trial · 1 indication
Primary outcome measure is based on the pharmacokinetic area under the concentration-time curve from time 0 to the last time point with a measurable concentration.
| Arm | Type | Description |
|---|---|---|
| Insulin Lispro A | EXPERIMENTAL | 20 units (U) subcutaneously (SC) |
| Insulin lispro B | ACTIVE_COMPARATOR | 20 units (U) subcutaneously (SC) |
| Name | Type | Description |
|---|---|---|
| Insulin lispro A | DRUG | 20 units (U) subcutaneously (SC). |
| Insulin lispro B | DRUG | 20 U subcutaneously (SC). |
Inclusion Criteria: * Are healthy males or females. * Body mass index (BMI) between 18.5 and 29.9 kilograms per meter squared (kg/m\^2) * Are nonsmokers. * Have normal blood pressure and pulse rate, a normal electrocardiogram (ECG), and clinical laboratory test results within normal reference range...